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ABSTRACT
Objective To quantify the prevalence of incidental
findings on magnetic resonance imaging (MRI) of the
brain.
Design Systematic review and meta-analysis of
observational studies.
Data sources Ovid Medline (1950 to May 2008), Embase
(1980 to May 2008), and bibliographies of relevant
articles.
Review methods Two reviewers sought and assessed
studies of people without neurological symptoms who
underwent MRI of the brain with or without intravenous
contrast for research purposes or for occupational,
clinical, or commercial screening.
Main outcomemeasuresOverall disease specific and age
specific prevalence of incidental brain findings,
calculated by meta-analysis of pooled proportions using
DerSimonian-Laird weights in a random effects model.
Results In 16 studies, 135 of 19559 people had
neoplastic incidental brain findings (prevalence 0.70%,
95% confidence interval 0.47% to 0.98%), and
prevalence increased with age (χ2 for linear trend,
P=0.003). In 15 studies, 375 of 15559 people had non-
neoplastic incidental brain findings (prevalence 2.0%,
1.1% to 3.1%, excluding white matter hyperintensities,
silent infarcts, and microbleeds). The number of
asymptomatic people needed to scan to detect any
incidental brain finding was 37. The prevalence of
incidental brain findings was higher in studies using high
resolution MRI sequences than in those using standard
resolution sequences (4.3% v 1.7%, P<0.001). The
prevalence of neoplastic incidental brain findings
increased with age.
Conclusions Incidental findings on brain MRI are
common, prevalence increases with age, and detection is
more likely using high resolution MRI sequences than
standard resolution sequences. These findings deserve to
be mentioned when obtaining informed consent for brain
MRI in research and clinical practice but are not sufficient
to justify screening healthy asymptomatic people.
INTRODUCTION
Apparently asymptomatic intracranial abnormalities
of potential clinical significance, or incidental brain
findings (box), are fast becoming problematic, with
the increasing use of magnetic resonance imaging
(MRI) of the brain by clinicians,1 researchers,2 and
companies that carry out health “check-ups.”3
The detection of incidental findings is an unintended
consequence of brain MRI in clinical situations where
the prevalence of any relevant finding is likely to be
low. Detection is potentially detrimental because the
treatment can have harmful as well as beneficial con-
sequences. Knowing the chance of discovering inci-
dental brain findings would help clinicians inform
patients of these risks, help researchers adequately
inform healthy volunteers in imaging research, and
adequately inform people who seek screening by
brain MRI.
The overall prevalence of incidental brain findings
including silent infarcts in a recent study of 2000 volun-
teers aged 46-97 years using high resolution MRI
sequences, without injected contrast or angiographic
sequences, wasmore than 10%.w1However, a systema-
tic review andmeta-analysis of the published literature
has been recommended4 because it could provide
Incidental brain findings on magnetic resonance imaging
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more precise estimates of the range of incidental find-
ings on brain MRI and explore the influence of study
design, patient characteristics, and imaging parameters
on the detection of incidental brain findings.
METHODS
In May 2008 we searched Ovid Medline from 1950
and Embase from 1980 (http://gateway.ovid.com,
see web extra appendix 1 for search strategy) for
reports on the use of brain MRI in healthy people,
volunteers, research controls, and people undergoing
commercial, clinical, or occupational screening. We
did not restrict the search by language or patients’
age. We supplemented the electronic searches with
surveillance of electronic tables of contents in neurolo-
gical journals andbyhand searching the bibliographies
of pertinent articles. Two authors (ZM and WNW or
RA-SS) read the title and abstract of every study iden-
tified by the electronic searches and critically
appraised the full text of potentially eligible studies.
We defined incidental brain findings as apparently
asymptomatic intracranial abnormalities that were
clinically significant because of their potential to
cause symptoms or influence treatment. We divided
the findings into two clinically relevant categories: neo-
plastic (benign and malignant tumours) and non-neo-
plastic (cysts, structural vascular abnormalities,
inflammatory lesions, and “other” such as hydrocepha-
lus, Arnold-Chiari malformations, and extra-axial col-
lections). Although white matter hyperintensities,
silent brain infarcts or lacune, and brain microbleeds
are incidental findings, we did not focus on them
because of their known increasing prevalence with
age,56 their largely unknown role in causing symp-
toms, and the current uncertainty about whether or
not to institute primary prevention after their
detection.6 We distinguished incidental brain findings
from normal variants, which we defined as anatomical
variants that do not have the potential to cause symp-
toms—for example, cavum septi pellucidi, large cis-
terna magna, and ventricular asymmetry.
We included studies published in full that reported
the prevalence of incidental brain findings in people
without neurological or psychiatric symptoms, who
underwent brain MRI as research cases or controls or
as recipients of commercial, clinical, or occupational
screening.Wedid not include studies restricted tomar-
kers of cerebrovascular disease because they have
recently been the subject of systematic reviews.5 6 Dis-
agreements about study eligibility were resolved by
discussion, or arbitration by one author (RA-SS). If
several publications arose from the same cohort, we
only included the largest study.
Data extraction
Two authors extracted data on study design, popula-
tion characteristics, and MRI parameters from each
study, and extracted the overall and age specific fre-
quencies of each type of incidental brain finding.
When age specific data on prevalence were not pro-
vided in an original publication we requested these
by emailing the corresponding author, who became a
coauthor of this review if they extracted and supplied
data.
Data analysis
We carried out a meta-analysis of prevalence data for
each incidental brain finding and all incidental brain
findings (excluding markers of cerebrovascular dis-
ease), using data from the studies that enabled relevant
calculations.We used the I2 statistic to estimate the het-
erogeneity of individual studies contributing to the
pooled estimate, and determined whether to use a
fixed or random effects model on this basis. We calcu-
lated the pooled proportion as the back transform of
the weighted mean of the transformed proportions,
using DerSimonian-Laird weights in a random effects
model,7 and report 95% confidence intervals. We did
subgroup analyses to explore the influence of theMRI
sequences used, the specialty of the person reporting
on the MRI, and participant characteristics on the
pooled prevalence of all incidental brain findings
(excluding markers of cerebrovascular disease).
When age specific data were provided in the original
publications or made available to us on request, we
calculated age specific prevalence in 20 year age
bands because 10 year age bands contained insufficient
data. The number of asymptomatic people needed to
scan to detect one incidental brain finding, or number
needed to scan, was the reciprocal of the prevalence
estimate. We used Confidence Interval Analysis
v2.1.2 to calculate 95% confidence intervals, and Stats-
Direct v2.7.2 for χ2 tests for trend, tests of heterogene-
ity, and meta-analysis of proportions with random
effects models.
RESULTS
The electronic search strategy identified 1862 publica-
tions, of which 19 papers reporting data on 17 cohorts
were eligible.8-10 w1-w16 We excluded three publications
because they reported on cohorts included in this sys-
tematic review at earlier stages in their recruitment,8 9
or because it was difficult to be certain that most parti-
cipants were asymptomatic for neurological
conditions.10
We included 16 publications reporting data between
1989 and 2008 on 16 unique cohorts (19 559 people)
from Asia (n=7277),w5 w10 w15 Europe (n=5942),w1 w2 w9
w11 w14 the United States (n=5764),w3 w4 w7 w8 w12 w13 and
Australia (n=576)w6 w16 who had undergone brain
MRI (table).w1-w16 The number of people in each
study ranged from 60 to 4000, with amean age of 11 to
63 years (range 1-97 years). One study included cases
(n=589) and controls (n=67),w12 but in the rest partici-
pants were exclusively controls (six studies,
n=1702),w2 w4 w6-w8 w13 cases (three studies, n=6739),w1
w3 w16 or screening attendees (six studies, n=11 118).w5
w9-w11 w14 w15
Critical appraisal
Participants had comorbidities in four studies, such as
hypertension,w9 w10 w12 diabetesmellitus,w9 w10myocardial
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infarction,w9 w10 and hyperlipidaemia,w10 but they did not
seem to have any comorbidities in seven studies, and no
comment wasmade in the remainder (table). The neuro-
logical asymptomatic status of participants was deter-
mined by historyw2 w6-w8 w12-w14 w16; history and
examinationw1 w3 w4 w10; history, examination, and investi-
gationw11; or unspecified means.w5 w9 w15 However, 21
(0.1%) of the 19559 participants had preceding neurolo-
gical symptoms that may have been related to abnorm-
alities found on brain MRI.w1 w3 w10 w16 No study
prespecified the potential incidental brain findings of
interest, and almost none was confirmed by pathology.
Only three studies defined normal variants (table).
The field strengths of the MRI magnets were
reported as 1.0 teslaw5 w10 w11 or 1.5 tesla,w1 w3 w6 w9 w13-
w16 or not reported.w2 w4 w7 w8 w12 None of the studies
published before 2002 used sequences regarded as
high resolution by modern standards (see web extra
table on bmj.com),w2-w5 and most subsequent studies
used lower resolution sequences (5 mm axial T2
weighted, axial or sagittal T1 weighted, axial or coro-
nal fluid attenuated inversion recovery, and axial pro-
ton density weighted sequences). Some recent studies
also included magnetic resonance angiographic
sequences,w4-w7 or high resolution sequences such as
three dimensional T1 spoiled or T2* gradient echo,w1
w6-w8 w11-w13 w16 or high resolution axial protondensity or
fluid attenuated inversion recovery. Abnormalities on
scans were interpreted by neuroradiologists,w3 w4 w6-w9
w12 w13 w16 a neuroradiologist or general radiologist,w15 a
neuroradiologist or neurologist,w1 general radio-
logists,w10 w11 w14 or unspecified observers.w2 w5
Disease specific and overall prevalence
Disease specific prevalence was calculable for intra-
cranial neoplasms in all 19 559 participants, but one
study of 4000 participants only described
asymptomatic tumours,w5 resulting in a denominator
of 15 559 for prevalence of non-neoplastic incidental
brain findings (fig 1). The I2 statistic ranged from 0%
for lowgradegliomas and cavernousmalformations, to
86% for arachnoid cysts, indicating variable degrees of
heterogeneity among the included studies. We there-
fore used a random effects model to meta-analyse the
data.
The prevalence of neoplastic incidental findings was
0.70% (95% confidence 0.47% to 0.98%), but descrip-
tion of the prevalence of each specific tumour type was
impaired by either a lack of subtypingw12 or non-speci-
fic classifications (for example, cerebellopontine angle
tumour,w11 unclassifiable fourth ventricular tumour,w11
hamartoma,w6 suprasellar tumourw16). The prevalence
of non-neoplastic incidental findings, excluding mar-
kers of cerebrovascular disease, was 2.0% (1.1% to
3.1%; fig 1). Arachnoid cysts were the single most pre-
valent incidental finding (0.5%, 0.21% to 0.87%), fol-
lowed by aneurysms (0.35%, 0.13% to 0.67%). The
combined prevalence of neoplastic and non-neoplastic
incidental findings was 2.7% (number needed to
scan=37).
Influence of MRI sequences, reporting, and participant
characteristics
Thedetectionof incidental findings (excludingmarkersof
cerebrovascular disease) was higher in studies using at
least one high resolution MRI sequence (318/6204;
4.3%, 3.0% to 5.8%)w1 w6-w8 w11-w13 w16 than in studies using
standard resolution sequences (176/9355; 1.7%, 1.1% to
2.4%, χ2 P<0.001).w2-w4 w9 w10 w14 w15 The detection of these
incidental findings in studies using neuroradiologists to
interpret images (272/8340; 3.5%, 1.8% to 5.7%)w1 w3 w4
w6-w9 w12 w13 w15 w16 was not significantly higher than in stu-
dies using general radiologists (144/4954; 2.3%, 0.9% to
4.4%, χ2 P=0.3).w10 w11 w14
Table 1 | Details of included studies
Study Country
Total
sample size
Mean (range)
age (years) % male Reason for imaging Comorbidities
Normal or normal
variants defined
Specialty
of scan readers
Wahlund 1989w2 Sweden 101 NS (NS) NS Research controls Absent No NS
Yue 1997w3 USA 3672 NS (≥65) NS Research cases NS No Neuroradiologist
Katzman 1999w4 USA 1000 29 (3-83) 55 Research controls Absent Yes Neuroradiologist
Onizuka 2001w5 Japan 4000 56 (24-85) 50 Commercial or clinical screening NS No NS
Lubman 2002w6 Australia 98 27 (NS) 63 Research controls Absent Yes Neuroradiologist
Kim 2002w7 USA 225 11 (0-18) 44 Research controls Absent No Neuroradiologist
Illes 2004w8 USA 151 47 (18-90) 54 Research controls Absent No Neuroradiologist
Goehde 2005w9 Germany 298 50 (31-73) 83 Commercial or clinical screening Present No Neuroradiologist
Tsushima 2005w10 Japan 1113 53 (22-84) 68 Commercial or clinical screening Present No General radiologist
Weber 2006w11 Germany 2536 21 (17-35) 100 Occupational screening Absent No General radiologist
Alphs 2006w12 USA 656 61 (35-82) 100 Research cases and controls Present No Neuroradiologist
Kumra 2006w13 USA 60 NS (10-21) NS Research controls Absent No Neuroradiologist
Baumgart 2007w14 Germany 1007 55 (40-67) 71 Commercial or clinical screening Present No General radiologist
Vernooij 2007w1 Netherlands 2000 63 (46-97) 48 Research cases NS Yes Neuroradiologist
or neurologist
Lee 2008w15 Taiwan 2164 52 (17-89) 57 Commercial or clinical screening NS No Neuroradiologist
or general radiologist
Kumar 2008w16 Australia 478 NS (60-64) 53 Research cases NS No Neuroradiologist
NS=not specified.
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To explore the influence of the source of the partici-
pants on prevalence of incidental brain findings, the
analyses were restricted to studies using at least one
high resolution MRI sequence or three dimensional
time of flight magnetic resonance angiography. The
prevalence was higher among research cases
(198/6150; 3.4%, 0.9% to 7.5%) than among attendees
of commercial screening (105/4582; 2.0, 0.9% to 3.3%)
and research controls (24/1635; 1.6%, 1.0% to 2.2%, χ2,
P<0.001). The overall prevalence did not differ
between studies in which comorbidities among partici-
pants were present (89/3074; 2.9%, 2.4% to 3.6%),
absent (134/4171; 3.2%, 2.7% to 3.8%), or unknown
(271/8314; 3.3%, 2.9% to 3.7%; χ2 P=0.6).
Age specific prevalence
Of the 16 included studies, the original data were no
longer available for two (totalling 5000 participants),w4 w5
one (2000 participants) declined to provide age specific
tabular data,w1 and five (totalling 1582 participants) failed
to contribute data on request,w2 w6-w8 w14 leaving age speci-
fic grouped summary data on 10977 people, which were
provided by six studiesw3 w9-w12 w15 and extracted from the
reports of two others with participants in just one 20 year
age band.w13 w16 No age specific data were available for
children aged 0-9 years, and after omitting 34 adults
aged 90-99, four 20 year age bands were left for analysis
of age specific prevalence (fig 2).We analysed age specific
data on white matter hyperintensities and silent brain
infarcts (although these data were unavailable in some
studiesw3 w10 w12 w16) simply to confirm that the data in the
included studies showed known age specific trends in the
prevalence of markers of cerebrovascular disease on
brainMRI.6 w1
These grouped summary data showed an increasing
prevalence with age for white matter hyperintensities
(χ2 for linear trend=71, P<0.001) and silent brain
infarcts (χ2 for linear trend=104, P<0.001), in keeping
with the findings of other studies.6 w1 The prevalence of
neoplastic incidental brain findings also increasedwith
age (χ2 for linear trend=8.8, P=0.003). The prevalence
of non-neoplastic incidental brain findings, however,
seemed to decline with age (χ2 for linear trend=6.9,
P=0.008; fig 2), although this trend was reversed in a
sensitivity analysis restricted to studies with age speci-
fic data that used at least one high resolution MRI
sequence (χ2 for linear trend=66, P<0.001; see web
extra appendix 2).w11 w12 w16
DISCUSSION
In this systematic review and meta-analysis of 16 stu-
dies totalling 19 559 participants, the overall preva-
lence of incidental brain findings on brain MRI was
2.7% (number needed to scan=37). In studies where
participants underwent at least one high resolution
MRI sequence—as is common practice in research
using brain imaging—the prevalence of incidental
brain findings (excluding markers of cerebrovascular
disease) was 4.3% (number needed to scan=23) com-
paredwith 1.7% (numberneeded to scan=59) in studies
using only low resolution sequences, which are cur-
rentlymost commonly used in clinical practice. Along-
side an expected age related trend in white matter
hyperintensities and silent brain infarcts, we found an
increasing prevalence of all neoplastic incidental brain
findings with age (fig 2), probably driven by the
increasing prevalence of meningiomas,w1 which were
the most common neoplastic incidental brain finding
(fig 1).
Strengths and weaknesses of this review
By synthesising all the published data on incidental
brain findings and adding unpublished datawhere pos-
sible, we increased the precision of existing estimates
of their prevalence across thewhole age range andused
a novel metric of the number needed to scan to detect
one incidental finding (fig 1). We included data on all
abnormalities, some of which were sought but not
detected by smaller studies—for example, arteriove-
nous malformations and colloid cysts were not
detected in a recent study.w1The influence of variations
in study design was diluted by pooling all the available
data, and we were able to explore this heterogeneity in
study characteristics and imaging sequences using
Neoplasia (n=19 559)
  Meningioma
  Pituitary adenoma
  Low grade glioma
  Acoustic neuroma
  Lipoma
  Epidermoid
  Unspecified neoplasm
Any neoplastic incidental finding
Structural vascular abnormalities (n=15 559)
  Aneurysm
  Cavernous malformation
  Arteriovenous malformation
Inflammatory lesions (n=15 559)
  Definite demyelination
  Possible demyelination
Cysts (n=15 559)
  Arachnoid cyst
  Colloid cyst
Other abnormalities (n=15 559)
  Chiari I malformation
  Hydrocephalus
  Extra-axial collection
Any non-neoplastic incidental
finding* (n=15 559)
0.29 (0.13 to 0.51)
0.15 (0.09 to 0.22)
0.05 (0.02 to 0.09)
0.03 (0.01 to 0.06)
0.04 (0.02 to 0.07)
0.03 (0.01 to 0.06)
0.09 (0.03 to 0.17)
0.70 (0.47 to 0.98)
0.35 (0.13 to 0.67)
0.16 (0.10 to 0.23)
0.05 (0.01 to 0.10)
0.06 (0.02 to 0.15)
0.03 (0.00 to 0.07)
0.50 (0.21 to 0.87)
0.04 (0.01 to 0.07)
0.24 (0.04 to 0.58)
0.10 (0.03 to 0.19)
0.04 (0.01 to 0.07)
2.00 (1.13 to 3.10)
72
27
8
5
6
3
14
135
67
23
7
9
4
99
2
71
15
4
375
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Prevalence (%)
(95% CI)
Prevalence (%)
(95% CI)
Number
with
abnormality
345
667
2000
3333
2500
3333
1111
143
286
625
2000
1667
3333
200
2500
417
1000
2500
50
Number
needed
to scan
 (n=19 559)
Fig 1 | Prevalence of some incidental findings (*excluding white matter hyperintensities,
microbleeds, and silent infarcts) on brain magnetic resonance imaging
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subgroup analyses. The provision of some unpub-
lished grouped summary data also enabled us to exam-
ine age specific prevalence.
Usingonlygrouped summarydatapreventedus from
exploring the influence of sex on the prevalence of inci-
dental brain findings found in other studies.11w7 w8 The
proportion of participants who actually had neurologi-
cal symptoms referable to apparently incidental brain
findings was low (0.1%); thismay be unavoidable, how-
ever, because some participants may attend for covert
investigationofundeclared symptoms,12whereasothers
may be serial attenders checking on undeclared under-
lying disease.13 A general problem, particularly in
research studies, is that many incidental brain findings
are not reported in the study papers because such peo-
ple are excluded at the point of recruitment, thereby
potentially underestimating the true prevalence.
Comparison with other studies
Our pooled estimate provides amore precise summary
of the existing data. The prevalence of incidental brain
findings described by other studies has varied, in part
because of the factors we have explored in sensitivity
analyses. Reassuringly, the age related trends in silent
brain infarcts andwhitematter hyperintensities that we
observed were consistent with existing population
based studies,6 which puts the other age related trends
in context (fig 2 and web extra appendix 2). Others
have foundan increasingprevalenceof some incidental
brain findings with age,w1 w6 w8 w12 but we were able to
classify them into neoplastic and non-neoplastic inci-
dental findings (fig 2) and confirm the robustness of
the trend in the prevalence of neoplastic incidental find-
ings in a sensitivity analysis (see web extra appendix 2).
One study has been published since we carried out our
literature search,14 although itwouldhavebeendifficult
to include these data because the scanning parameters
varied considerably during the study period.
Implications for clinical practice, research, and screening
A major dilemma is whether to treat incidental brain
findings and, if so, how. But the evidence is insufficient
on what to do with most of them, partly because of the
lack of controlled trials of their treatments and partly
because the availability of MRI for only 20-30 years
means that the long term prognosis is unknown. For
example, the risk of haemorrhage from most unrup-
tured aneurysms seems to be low15 yet the risk of
death and stroke from interventional treatment is
sizeable.16 However, awareness of the presence of an
unruptured intracranial aneurysm might lead to better
modification of risk factors and potential benefits from
interventional treatment.A randomised controlled trial
is under way to address this dilemma (www.teamstudy.
org). Treatment of unruptured brain arteriovenous
malformations is independently associated with poor
outcome in the short term,17 which has also led to an
ongoing randomisedcontrolled trial (www.arubastudy.
org). Although repeated scanning has become com-
monplace for asymptomatic meningiomas, about 94%
remain asymptomatic, about 63%donot grow, and sur-
gery carries a fair risk of morbidity, such that conserva-
tive management is generally recommended.18
Whether early treatment with surgery, radiotherapy,
or chemotherapy improves symptom free survival for
patients with low grade glioma is unknown.19
Some have suggested a subdivision of incidental
brain findings by the perceived need and urgency of
referral to a specialist.20 But the urgency of referral is
difficult to gauge given the paucity of robust evidence
about whether and how best to treat any of the asymp-
tomatic incidental findings reported. The clinical
urgency will vary according to the age and healthiness
of the patient, and the perceived urgency may change
over time as knowledge about the effects of treatment
changes.14 Thismay explainwhy studies have varied—
for example, some have classified arachnoid cysts as
not requiring referral,w7 whereas others have referred
peoplewith these cysts for urgent clinical assessment.w4
Apreferable pragmatic approach is tomanage imaging
results with a degree of urgency on the basis of the
likely overall benefit to the study participant.4
Apart from the harm that may arise from the lack of
evidence onwhich to base themanagement of inciden-
tal brain findings, the detection of such findings can
provoke considerable anxiety about a “possible
abnormality” (which might be a false positive
result)w13; involve a costly cascade of further investiga-
tions,with risks of complications (in the case of catheter
angiography or brain biopsy); lead to costly medical
opinions; and worry patients about the consequences
of an untreated finding. For the patient, the discovery
of an incidental brain findingmay result in loss of their
driving licence, life insurance, and even
employment.21
The prevalence of incidental brain findings, the
shortage of evidence on which to base their manage-
ment, and the other harmful consequences of their dis-
covery should provoke caution in a variety of settings.
Clinicians should be cautious about investigations for
reassuring patients because even the anxiolytic effects
of having normal results on brain MRI are sustained
for only a few months.22 At the very least clinicians
Age (years)
Pr
ev
al
en
ce
 (%
)
10-29
0
5
10
15
20
25
30-49 50-69 70-89
Neoplastic incidental brain findings
Non-neoplastic incidental brain findings
Silent infarcts
White matter hyperintensities
(n
=2
63
0)
(n
=2
63
0)
(n
=2
63
0)
(n
=2
62
3)
(n
=1
50
8)
(n
=1
50
8)
(n
=1
50
8)
(n
=1
06
2)
(n
=3
28
8)
(n
=3
28
8)
(n
=2
89
5)
(n
=1
23
4)
(n
=3
51
7)
(n
=3
51
7)
(n
=2
72
)
(n
=1
39
)
Fig 2 | Prevalence of neoplastic incidental findings, non-
neoplastic incidental findings, silent infarcts, and white
matter hyperintensities, with 95% confidence intervals
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should counsel patients about the chance of incidental
findings before requesting brain MRI. Volunteers for
research studies using brain MRI should be informed
of the chance and consequences of discovering an inci-
dental abnormality, and research centres need to have
mechanisms in place to deal with these once found.2
Furthermore, the increasing number of screening com-
panies that provide “health check-ups” (especially in
countries with widespread availability of brain
MRI),3 23 has attracted caution from only a few regula-
tory bodies.24 25 In such screening the actual objective is
the discovery of incidental brain findings, which may
be regarded by the client as fortuitous.3 12 Although
true negative results from brain MRI may be reassur-
ing, many of the requirements of a screening test are
not fulfilled; most of all, the overall benefit of such
screening on quality adjusted life years is unproved.
The cost effectiveness of screening using brain MRI
also seems unfavourable: in a study in Japan the cost
for the identification of one person with an incidental
abnormality requiring further evaluation was $24 733
(£14 994; €17 389),w10 and screening is not even
thought to be cost effective for some of the more wor-
rying incidental brain findings such as aneurysms26 and
silent brain infarcts.6 Consequently, guidance from
professional organisations such as the American
Heart Association has cautioned against screening the
general population for particular conditions, such as
intracranial aneurysms.27 People purchasing a health
check-up brainMRI froma screening company should
be able to consider the consequences on the basis of
clear information about the prevalence of incidental
findings and the potentially detrimental effects of dis-
covering them,28 especially in the light of a recent
review of direct to consumer marketing information
in the United States, most of which failed to provide
comprehensive balanced information, including the
risks of having a scan.29
Implications for future research
Ameta-analysis of studies on incidental brain findings
using individual patient data is the only way to disen-
tangle the various influences that we have found on
prevalence, including characteristics of the partici-
pants, the imaging sequences used, and who reports
them. For example, reporting age specific data will
help confirm the age related trends described in this
review. Furthermore, future studies of the prevalence
of incidental brain findings would benefit from defini-
tions and normal variants being prespecified.
Guidance on the wide variety of ethical issues con-
cerning the participation of healthy volunteers in brain
imaging research is beginning to emerge.2 4 30 In future
studies, volunteers should be provided with accurate
information on the prevalence of incidental brain find-
ings as part of the informed consent process, pointing
out the higher detection in studies using high resolu-
tion MRI sequences. A mechanism for dealing with
potential abnormalities that is appropriate to the
research setting should be in place.2
Conclusions
Doctors who request scans in clinical practice or who
recommend screening for health check-ups, and
researchers who obtain consent from volunteers,
should provide information about the prevalence of
incidental brain findings on brainMRI, the higher pre-
valence with high resolution MRI sequences, and the
shortage of evidence to inform their management.
We thank the Edinburgh Stroke Research Group for its comments.
Contributors: RA-SS, WW, CPW, JMW, and ZM conceived and designed
the study. ZM, WW, and RA-SS collected and analysed the data. WTL, FW,
Y-CL, YT, HA, and SCL extracted and contributed additional grouped
summary data from studies included in this review. RA-SS, ZM, and WW
wrote the paper. All authors had full access to the data in the study, can
take responsibility for the integrity of the data and the accuracy of the
data analysis, and edited and approved the final version. RA-SS is the
guarantor.
Funding: The Chief Scientist Office of the Scottish Government supports
WW with a Clinical Academic Training Fellowship, and ZM with a research
and development infrastructure award for radiology to Lothian
Universities Hospitals NHS Trust Research and Development Office. The
UK Medical Research Council supports RA-SS with a clinician scientist
fellowship. JMW is partly supported by the Scottish Funding Council and
Chief Scientist Office through the SINAPSE (Scottish Imaging Network. A
Platform for Scientific Excellence) Collaboration (www.sinapse.ac.uk).
The Cardiovascular Health Study is funded by the National Heart, Lung,
and Blood Institute. The researchers are independent of the funders, and
the study sponsors had no role in the study design; the collection,
analysis, and interpretation of data; the writing of the report; and the
decision to submit the article for publication.
Competing interests: None declared.
Ethical approval: Not required.
1 Peterson CL, Burton R. US health care spending: comparison with
other OECD countries. 15. Congressional Research Service. CRS
Report for Congress, 2007.
2 Illes J, Kirschen MP, Edwards E, Bandettini P, Cho MK, Ford PJ, et al.
Practical approaches to incidental findings in brain imaging
research. Neurology 2008;70:384-90.
3 Al-Shahi Salman R, Whiteley WN, Warlow C. Screening using whole-
body magnetic resonance imaging scanning: who wants an
incidentaloma? J Med Screen 2007;14:2-4.
4 Wolf SM, Lawrenz FP, Nelson CA, Kahn JP, ChoMK, Clayton EW, et al.
Managing incidental findings in human subjects research: analysis
and recommendations. J Law Med Ethics 2008;36:219-48.
5 Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain
microbleeds: systematic review, subgroup analyses and standards
for study design and reporting. Brain 2007;130:1988-2003.
6 Vermeer SE, Longstreth Jr WT, Koudstaal PJ. Silent brain infarcts: a
systematic review. Lancet Neurol 2007;6:611-9.
7 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
Trials 1986;7:177-88.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Brain magnetic resonance imaging (MRI) is widely used in research and clinical practice and
can be purchased for health screening purposes
Brain MRI detects incidental findings in people with asymptomatic neurological conditions
Precise estimates of the frequency of incidental findings and influences on their detection are
yet to be determined
WHAT THIS STUDY ADDS
The crude prevalence of incidental findings on brain MRI is 2.7%, or one for every 37
neurologically asymptomatic people scanned
Incidental brain findings are more likely to be detected in studies using at least one high
resolution MRI sequence than studies using standard sequences (4.3% v 1.7%)
The frequency of incidental findings should be discussed when obtaining consent for brain
MRI in research and is relevant to clinical practice, but alone does not justify health screening
RESEARCH
page 6 of 7 BMJ | ONLINE FIRST | bmj.com
8 Weber F, Knopf H. Cranial MRI as a screening tool: findings in 1,772
military pilot applicants. Aviation Space Environment Med
2004;75:158-61.
9 Göhde SC, Goyen M, Forsting M, Debatin JF. [Prevention without
radiation-a strategy for comprehensive early detection using
magnetic resonance tomography]. [German]. Radiologe
2002;42:622-9.
10 Meadows J, Kraut M, Guarnieri M, Haroun RI, Carson BS.
Asymptomatic Chiari type I malformations identified on magnetic
resonance imaging. J Neurosurg 2000;92:920-6.
11 Sawamura Y, Ikeda J, Ozawa M, Minoshima Y, Saito H, Abe H.
Magnetic resonance images reveal a high incidenceof asymptomatic
pineal cysts in young women. Neurosurgery 1995;37:11-5.
12 Mamourian A. Incidental findings on research functional MR images:
should we look? AJNR Am J Neuroradiol 2004;25:520-2.
13 Pickard JD, Gillard JH. Guidelines reduce the risk of brain-scan shock.
Nature 2005;435:17.
14 Hoggard N, Darwent G, Capener D, Wilkinson ID, Griffiths PD. The
high incidence and bioethics of findings on magnetic resonance
brain imaging of normal volunteers for neuroscience research. J Med
Ethics 2009;35:194-9.
15 Wiebers DO, Whisnant JP, Huston J, III, Meissner I, Brown RD Jr,
Piepgras DG, et al. Unruptured intracranial aneurysms: natural
history, clinical outcome, and risks of surgical and endovascular
treatment. Lancet 2003;362:103-10.
16 Lanterna LA, Tredici G, Dimitrov BD, Biroli F. Treatment of unruptured
cerebral aneurysmsby embolizationwith guglielmi detachable coils:
case-fatality, morbidity, and effectiveness in preventing bleeding—a
systematic review of the literature. Neurosurgery 2004;55:767-75.
17 Wedderburn CJ, van Beijnum J, Bhattacharya JJ, Counsell CE,
Papanastassiou V, Ritchie V, et al. Outcome after interventional or
conservative management of unruptured brain arteriovenous
malformations: a prospective, population-based cohort study.
Lancet Neurol 2008;7:223-30.
18 Yano S, Kuratsu J, Kumamoto Brain Tumor Research Group.
Indications for surgery in patients with asymptomatic meningiomas
based on an extensive experience. J Neurosurg 2008;105:538-43.
19 Cavaliere R, Lopes MB, Schiff D. Low-grade gliomas: an update on
pathology and therapy. Lancet Neurol 2005;4:760-70.
20 Bryan RN, Manolio TA, Schertz LD, Jungreis C, Poirier VC, Elster AD,
et al. Amethod for usingMR to evaluate the effects of cardiovascular
disease on the brain: the cardiovascular health study. AJNR Am J
Neuroradiol 1994;15:1625-33.
21 Piatt JH Jr. Unexpected findings on brain and spine imaging in
children. Pediatr Clin North Am 2004;51:507-27.
22 HowardL,WesselyS, LeeseM,Page L,McCroneP,HusainK, et al. Are
investigations anxiolytic or anxiogenic? A randomised controlled trial
of neuroimaging to provide reassurance in chronic daily headache. J
Neurol Neurosurg Psychiatry 2005;76:1558-64.
23 Komotar RJ, Starke RM, Connolly ES. Brain magnetic resonance
imaging scans for asymptomatic patients: role in medical screening.
Mayo Clin Proc 2008;83:563-5.
24 Health Canada.Whole body screening using MRI or CT technology.
Ottawa, ON; Health Canada, 2003.
25 Royal Australian andNewZealandCollege of Radiologists. The use of
diagnostic imaging for screening purposes and non-referred
investigations: RANZCR statement of principles. Sydney, Australia:
RNAZCR, 2005.
26 Yoshimoto Y, Wakai S. Cost-effectiveness analysis of screening for
asymptomatic, unruptured intracranial aneurysms. A mathematical
model. Stroke 1999;30:1621-7.
27 Bederson JB, Awad IA, Wiebers DO, Piepgras D, Haley EC Jr, Brott T,
et al. Recommendations for the management of patients with
unruptured intracranial aneurysms: a statement for healthcare
professionals from the Stroke Council of the American Heart
Association. Stroke 2000;31:2742-50.
28 Entwistle VA, Carter SM, Trevena L, Flitcroft K, Irwig L, McCaffery K,
et al. Communicating about screening. BMJ 2008;337:a1591.
29 Illes J, Kann D, Karetsky K, Letourneau P, Raffin TA,
Schraedley-Desmond P, et al. Advertising, patient decision making,
and self-referral for computed tomographic andmagnetic resonance
imaging. Arch Intern Med 2004;164:2415-9.
30 Seixas D, Ayres Basto M. Ethics in fMRI studies. A review of the
EMBASE and MEDLINE literature. Clin Neuroradiol 2008;18:79-87.
Accepted: 27 May 2009
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 7
